InnoCare presented data on their drug pipeline at the European Hematology Association (EHA) 2023 Hybrid Congress. The company's orelabrutinib, an inhibitor of Bruton’s Tyrosine Kinase, was evaluated in a study to treat Primary Immune Thrombocytopenia. Results showed that both doses of orelabrutinib were safe for patients with ITP, and those who had previously responded to glucocorticoids or intravenous immunoglobulin therapies showed better efficacy when treated with the higher dose. Two poster presentations showcased the potential of orelabrutinib plus R-CHOP-like regimen for non-GCB DLBCL and a chemo-free combination of Pomalidomide, Orelabrutinib, Rituximab with Sequential high-dose Methorexate in Newly Diagnosed Primary CNS Lymphoma. Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Keywords: InnoCare, pipeline, orelabrutinib, Primary Immune Thrombocytopenia, poster presentations
InnoCare has presented data on their robust pipelines at EHA 2023